Does estrogen therapy still raise stroke risk?

Whether estrogen therapy raises stroke risk depends on many personal health factors — including age, route of administration, dose, and underlying cardiovascular history — that cannot be assessed through website content alone. Per FDA black box warnings on estrogen and progestogen products, these medications increase the risk of deep vein thrombosis, pulmonary embolism, and stroke. A prescriber should evaluate each individual's complete medical profile before initiating or continuing therapy.

What the evidence shows about stroke risk and estrogen

According to the WHI long-term follow-up data, oral estrogen therapy was associated with a modest increase in ischemic stroke risk, particularly in women who initiated therapy after age 60 or more than 10 years after the onset of menopause. Per published clinical guidelines, this risk is believed to be related to the hepatic first-pass effect of oral estrogen, which can modestly elevate coagulation factors.

According to current NAMS guidelines, transdermal estrogen — delivered via patch, gel, or spray — bypasses hepatic metabolism and does not produce the same effect on coagulation markers. Per the Endocrine Society, observational data consistently indicate that low-to-moderate dose transdermal estrogen is associated with a substantially lower stroke risk profile compared to oral formulations, including in women with some cardiovascular risk factors.

Per published clinical guidelines, the timing of initiation also matters. Women who begin therapy earlier — generally within 10 years of menopause onset and before age 60 — tend to have a more favorable cardiovascular risk profile than those who begin later.

Risk categories by patient profile

• Lower observed risk: According to current NAMS guidelines, healthy women under 60 or within 10 years of menopause onset using transdermal estrogen at appropriate doses represent the lowest-risk group in available data.
• Intermediate considerations: Women over 60 initiating estrogen for the first time, particularly with oral formulations, warrant careful individualized risk assessment per published clinical guidelines.
• Elevated baseline risk: Per FDA-approved prescribing information, women with a personal history of stroke, thromboembolism, clotting disorders, or uncontrolled hypertension carry materially higher risk and require specialist evaluation before any hormonal therapy is considered.

Factors that may reduce risk

• Route of delivery: Per published clinical guidelines, transdermal administration is generally preferred over oral estrogen when stroke risk is a clinical concern.
• Dose: According to current NAMS guidelines, using the lowest dose that adequately addresses symptoms is a core prescribing principle.
• Blood pressure management: Per published clinical guidelines, uncontrolled hypertension is a substantially stronger independent stroke risk factor than estrogen therapy; blood pressure control is an important part of any HRT risk assessment.
• Timing of initiation: According to the WHI long-term follow-up data, initiating therapy earlier in the menopause transition is associated with a more favorable cardiovascular risk profile.

A note on compounded estrogen preparations

Some patients use compounded estrogen formulations when commercially available products do not meet their clinical needs. Compounded medications are not FDA-approved. They have not been reviewed by the FDA for safety, effectiveness, or quality. FDA-approved medications should be considered first when commercially available options meet patient needs.

The bottom line

Whether HRT is appropriate for individuals concerned about stroke risk depends on many personal health factors that cannot be assessed through website content alone. According to current NAMS guidelines, for many healthy women in their 40s and 50s using transdermal estrogen, the incremental stroke risk is low — but this must be weighed individually. A prescriber should determine the most appropriate formulation, dose, and route of administration based on a patient's complete medical history and cardiovascular risk profile.